Abstract: Compounds, compositions and methods are provided for treating the FXR-mediated disease or process in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound claimed, wherein the FXR-mediated disease or condition linked to chronic liver diseases such as nonalcoholic fatty liver disease and nonalcoholic steatohepatitis; gastrointestinal diseases; cardiovascular diseases; metabolic diseases such as diabetes and obesity; inflammation, or cancer etc.

Abstract: The present invention relates to a method for quantitative detection of anti-HBc and its use in monitoring disease progression of chronic hepatitis B patients and predicting therapeutic effects. By quantitative detection of antibodies against hepatitis B core protein (Anti-HBc), it is able to monitor disease progression of chronic hepatitis B patients, effectively predict therapeutic effects in chronic hepatitis B patients who accept a therapy against hepatitis B virus (especially, a therapy based on interferon and a therapy based on nucleoside/nucleotide analog anti-HBV drug), and thus guide the patients to reasonably choose drugs.

Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 11, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.

Abstract: A method for accurately producing the drilled hole in a wall of a component fabricated by investment casting process, such as for use in a blade or steam turbine includes the following steps. The 3D data of actual component is obtained from the measurements or from the numerical simulation. The actual model and the ideal model are aligned and compared, a series of cutting planes are given to establish a series of 2D cross-sections of the actual and ideal models after registration. Each cross-section is dispersed into discrete points, the distance between each corresponding points are calculated and formed into 2D displacement. The accurate parametric model consisting of the depth, hole center, and the nominal vector is obtained on the basis of considering the deviations in geometrical and positional values. The drilled hole is then produced according to the corrected parametric drilled-hole geometrical and positional value.

Abstract: This present disclosure relates to a method for preparation of polyvinylidene fluoride membrane with functional anthraquinones. The method is carried out according, to the following steps: step 1: preparing 2-(1-hydroxy-3-butene)-1,4,5,8-tetramethoxyl naphthalene; step 2: preparing polyvinylidene fluoride-aromatic ether copolymers: polyvinylidene fluoride was used as the initiator, 2-(1-hydroxy-3-butene) -1,4,5,8-tetramethoxynaphthalene was the monomer, N,N-dimethylformamide was solvent, cuprous chloride/Me6TREN was the catalytic, polyvinylidene fluoride-aromatic ether copolymer was synthesized by atomic transfer radical polymerization; step 3: reducing the polyvinylidene fluoride-aromatic ether copolymer to quinone by demethoxy oxidation; step 4: using the product of step 3 and N, N-dimethylformamide a film-forming reagents, then scraping into a membrane. Further, the anthraquinone which fixed in the polyvinylidene fluoride membrane would not fall off.

Abstract: Provided are an ORF7 deficient varicella virus, an vaccine comprising the virus and use thereof, as well as a method for the production the virus.

Abstract: The invention relates to a method for preparing double-layered virus-like particles of rotavirus in vitro. The method comprises the following steps: purifying rotavirus VP6 proteins from a lysis supernatant, and in vitro assembling double-layered virus-like particles consisting of VP2 proteins and VP6 proteins, wherein the proteins and the virus-like particles can be used for preventing or reducing the clinical symptoms caused by rotavirus infection.

Abstract: The present invention relates to an epitope peptide (or a variant thereof) which can be used in the prevention of respiratory syncytial virus (RSV) infection, a recombinant protein comprising the epitope peptide (or a variant thereof) and a carrier protein, and uses of the epitope peptide (or a variant thereof) and the recombinant protein. The present invention also relates to an antibody against the epitope peptide, a cell line for generating the antibody, and uses thereof. Furthermore, the present invention also relates to a vaccine or a pharmaceutical composition comprising the recombinant protein or the antibody according to the invention, for preventing one or more symptoms associated with RSV infection.

Abstract: The present invention provides application of camptothecin and derivatives thereof as antifouling agent, relating to camptothecin. Application of camptothecin and derivatives thereof as antifouling agent for facilities in water is provided, wherein the antifouling agent contains camptothecin and/or at least one of its derivatives. The application of camptothecin and derivatives thereof as antifouling agent for facilities in water can be used to prevent attachment of marine or freshwater micro-fouling organisms and/or large fouling organisms to the surfaces of facilities in the sea, lake, river or pool. The antifouling agent may also be used in mixture with other antifouling substance. Antifouling method for artificial facilities in water is provided. An antifouling paint for facilities in water is provided. Camptothecin and its derivatives have significant inhibitory activity to the attachment of fouling organisms, i.e.

Abstract: The present invention provides a POSS-containing in-situ composite nanogel with magnetic responsiveness and the method for preparing the same, wherein POSS-containing macromolecule capable of polymerizing and metal-coordination complexing is synthesized to complex with iron salt, Fe2+/Fe3+ salts are in-situ deposited via chemical coprecipitation, and crosslinking agent and initiator are added to induce polymerization so that POSS-containing nanogel ranges with magnetic responsiveness is obtained. The present invention is of professional design, feasible technique and simple operation, and prepared nanogel magnetic particles are well dispersed with excellent magnetic responsiveness, which possesses a good application prospect in medical diagnosis, sensor, catalyst carrier and biomaterial.

Abstract: Provided in the present invention are a diphtheria toxin non-toxic mutant CRM197 or a fragment thereof as an adjuvant in a fusion protein and the use thereof to enhance the immunogenicity of a target protein fused therewith, for example, an HEV capsid protein, or an influenza virus M2 protein or an immunogenic fragment thereof. Also provided is a method for enhancing the immunogenicity of a target protein, comprising the fusion expression of the CRM197 or the fragment thereof with the target protein to form a fusion protein. Further provided is a fusion protein comprising the CRM197 or the fragment thereof and a target protein, the CRM197 or the fragment thereof enhancing the immunogenicity of the target protein. The present invention also provides an isolated nucleic acid encoding the fusion protein, a construct and a vector comprising said nucleic acid, and a host cell comprising the nucleic acid.

Abstract: Provided in the present invention are a diphtheria toxin non-toxic mutant CRM197 or a fragment thereof as an adjuvant in a fusion protein and the use thereof to enhance the immunogenicity of a target protein fused therewith, for example, an HEV capsid protein, or an influenza virus M2 protein or an immunogenic fragment thereof. Also provided is a method for enhancing the immunogenicity of a target protein, comprising the fusion expression of the CRM197 or the fragment thereof with the target protein to form a fusion protein. Further provided is a fusion protein comprising the CRM197 or the fragment thereof and a target protein, the CRM197 or the fragment thereof enhancing the immunogenicity of the target protein. The present invention also provides an isolated nucleic acid encoding the fusion protein, a construct and a vector comprising said nucleic acid, and a host cell comprising the nucleic acid.

Abstract: The present invention relates to epitope peptides (or mutants thereof) for treating hepatitis B virus infection, recombinant proteins comprising such epitope peptides (or mutants thereof) and carrier proteins, and uses of such epitope peptides (or mutants thereof) and recombinant proteins. The present invention also relates to antibodies against such epitope peptides, cell lines producing said antibodies, and uses thereof. Furthermore, the present invention relates to vaccines or pharmaceutical compositions for treating or alleviating one or more symptoms associated with hepatitis B virus infection, which comprise the recombinant proteins or antibodies according to the invention, respectively.

Abstract: The invention relates to a truncated L1 protein of the Human Papillomavirus Type 6, a virus-like particle consisting of the truncated L1 protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.

Abstract: Provided are an N-terminal truncated L1 protein of the Human Papillomavirus Type 58, a coding sequence and preparation method thereof, and a virus-like particle comprising the protein. Uses of the protein and the virus-like particle in the preparation of a pharmaceutical composition or a vaccine are further provided. The pharmaceutical composition or vaccine is used for prevention of HPV infection and a disease caused by HPV infection.

Abstract: The present invention provides a kind of inherent flame retardant rigid polyurethane foam. The production formula comprises 100 to 105 pbw of polyether polyol and reactive phosphorus-containing flame retardant, 2.5 to 3.5 pbw of amine catalyst, 0.8 to 2.5 pbw of tertiary amine catalyst, 0.8 to 2.5 pbw of foam stabilizer, 0.5 to 1.5 pbw of blowing agent, 135 to 150 pbw of isocyanates, and 0.05 to 0.1 pbw of organo-metallic catalyst, wherein the reactive phosphorus-containing flame retardant is 9,10-dihydro-9-oxa-10-phosphaphenanthrene-4-hydroxybenzyl alcohol. The active monomers containing flame retarding elements are introduced into main chain and side chain of PU for modification, which permanently improves the flame retardancy of PU without obvious effect on other performance of PU matrix.

Abstract: A quantitative analysis method based on air pressure measuring, which can be used for the high-sensitivity quantitative detection of various targets i.e. inorganic ions, small molecules and biological macromolecules such as proteins, DNA, and even viruses, bacteria, cells, etc. The present invention catalyzes hydrogen peroxide to generate a large amount of gas using enzymes or nanoparticles, etc.; converts the target molecule detection signal into a gas pressure intensity signal; achieves signal amplification; and finally converts the pressure change into an electrical signal to conduct a reading through an air pressure meter, thereby achieving high-sensitivity quantitative detection. The feasibility, wide applicability and reliability of the present invention are certified through three different detection systems, i.e. an ELISA system, a DNA hydrogel system and a functional DNA sensor system, respectively, using an air pressure meter.

Abstract: The invention relates to antibodies recognizing epitopes on HA1 domain of hemagglutinin (HA) protein of influenza virus, cell lines for producing the antibodies, and uses thereof. The antibodies according to the invention can specifically bind to HA1 domain of different HA subtypes and specifically bind to HA1 domain of hemagglutinin (HA) protein of H1 subtype (including seasonal H1N1 and 2009 pandemic H1N1) and H5 subtype of influenza viruses. Therefore, the invention also relates to vaccines or pharmaceutical compositions for preventing and/or treating infection of H1 subtype and H5 subtype influenza virus and/or a disease caused by the infection (e.g. influenza), comprising the antibodies according to the invention.

Abstract: The present invention provides a type of cost-effective sulfur-based transition metal composite as the negative electrode active material for lithium ion batteries with high capacity. Moreover, a non-aqueous secondary battery using this negative electrode with long cycle life and high capacity is provided. The battery contains a positive electrode, negative electrode, separator, and non-aqueous electrolytes. The negative electrode contains at least one kind of sulfur-based transition metal composites provided in the present invention.

Abstract: Provided herein are methods and compositions related to a retinoid receptor-selective pathway. As described herein, this pathway can be targeted to manipulate a tumor microenvironment. For example, the methods and compositions described herein can be used to induce apoptosis in a cancer cell. Further, the compositions described herein, including Sulindac and analogs thereof, can be used to target this pathway for the treatment or prevention of cancer in human patients.